Trial | Population | Dexrazoxane Use (% use) | Cumulative Doxorubicin Dose (mg/m²) | Number of Patients | Age Range (years) | Heart Failure Incidence** | LVEF Decline ¶ (%) |
---|---|---|---|---|---|---|---|
LMS 04 Pautier et al. 2024 [22] | Leiomyosarcoma | No | 360–450‡ | 149 | 30–86 | 5.4 | NA |
ANNOUNCE (< 450 mg/m²) Jones et al. 2021 [27] | Soft-Tissue Sarcoma | Yes (38.6%) | < 450 | 153 | NA* | 2 | 16.2 (with dexrazoxane) 5.9 (without dexrazoxane) |
ANNOUNCE (450–599 mg²) | Soft-Tissue Sarcoma | Yes (88.5%) | 450–599 | 159 | NA* | 3 | 9.9 (with dexrazoxane) 23.5 (without dexrazoxane) |
ANNOUNCE (≥ 600 mg²) | Soft-Tissue Sarcoma | Yes (90%) | ≥ 600 | 89 | NA* | 1.1 | 12.5 (with dexrazoxane) 44.4 ( without dexrazoxane) |
P 9754 Schwartz et al. 2016 [29] | Pediatric Osteosarcoma | Yes (100%) | 450–600 | 242 | 3–30 | 0 | 2.1† |